With the discovery of the ara-CTPase activity of the dNTP triphosphohydrolase SAM and HD domain-containing protein-1 (SAMHD1) resulting in limited ara-C activity in SAMHD1+ cancer cells as well as xenograft models, SAMHD1 was proposed as a novel target in AML patients [102,103,104]. Here, SAMHD1 is linked to cancer.